RxDoctor Payments Data

Waldemar Sternbergh, MD

Vascular Surgery · New Orleans, LANPI 1811939648

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by W. L. Gore & Associates, Inc. at 55.2% of the total.

$11,460in general payments, 2019–2025

Across 124 payments — averaging $92.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$6K
  • Medtronic$1K
  • Silk Road Medical, Inc.$1K
  • Cook Medical LLC$977
  • Surmodics, Inc.$310
  • Bolton Medical Inc$295
  • plus $1K from 14 others
$35,117in research payments, 2019–2025

Across 24 payments — averaging $1463.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$19K
  • Bard Peripheral Vascular, Inc.$16K
  • C. R. Bard, Inc. & Subsidiaries$235

What the payments were for

  • Travel & lodging$6936%
  • Food & beverage$10,76794%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,460 in reported general payments places this provider in the 70th percentile of 65 vascular surgery providers in Louisiana.

See all vascular surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$75,202
Medicare patients
235
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$23,136
Pentoxifylline11$318
ClopidogrelClopidogrel Bisulfate31$255

Paid to pharmacies, not to this prescriber.

Other vascular surgery in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →